At the news
? NEUTRALIMPACT 4/10 8-K filed Feb 27, 2026 at 08:25 ET
TransMedics provided additional details on its Q4 2025 financial results, clarifying that the previously reported $105.4 million net income included a one-time $83.8 million tax benefit from releasing a $103.3 million U.S. valuation allowance. Adjusted net income for the quarter was $17.5 million. The company reaffirmed its expectation of future tax provisions aligning with statutory rates.
- TransMedics released a $103.3 million U.S. tax valuation allowance in Q4 2025, resulting in an $83.8 million net income tax benefit.
- Reported Q4 2025 net income was $105.4 million; adjusted net income, excluding the tax benefit, was $17.5 million.
- The annual effective tax rate for 2025 was (77.0)%, but would have been 19.1% without the valuation allowance release.
- The company expects future quarterly tax provisions to be in line with U.S. statutory corporate income tax rates.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access